HK Stock Market Move | KINTOR PHARMA-B(09939) rose more than 8% in the morning. The company is actively advancing the preparation work for the KT-939 registration application.

KINTOR PHARMA-B(09939) rose by more than 8% in the morning session, at the time of writing, it had increased by 8.52%, closing at HK$2.42 with a trading volume of HK$9.6388 million. On the news front, on September 9th, KINTOR PHARMA-B announced that the human long-term safety trial of their self-developed novel efficient tyrosinase inhibitor KT-939, which inhibits melanin production, has been completed with all 130 participants enrolled. KT-939 can accurately target tyrosinase, effectively blocking the oxidation process of tyrosine, thereby inhibiting melanin production, and also possessing antioxidant and anti-inflammatory effects, which gives it outstanding advantages in the efficacy and safety of cosmetics. As of the date of this announcement, KT-939 has completed several safety and toxicology evaluation tests as well as a 28-day continuous human efficacy trial for topical use. The results of the trials showed that KT-939 performed well in terms of efficacy and safety. Based on previous comparisons of the efficacy and safety of KT-939 with commonly used whitening ingredients such as Thiamidol and 377, the company is actively preparing for the registration application of KT-939 and plans to officially submit it to the Chinese drug regulatory authority in the third quarter of next year. The tyrosinase inhibitor Thiamidol, which targets melanin production by the same mechanism, was approved by the Chinese drug regulatory authority in November 2024, becoming the first and only whitening cosmetic ingredient to be approved since the implementation of the Cosmetics Supervision and Administration Regulations in 2021. It is also the second whitening cosmetic ingredient to be approved domestically in 12 years after 377. KT-939 is expected to become the first domestically developed and approved whitening cosmetic ingredient, achieving a "zero breakthrough" in China's completely independent intellectual property in this field, providing a new choice for the domestic and global market for pigmentation whitening cosmetics.